Streetbeat News

Price Targets

DAR

Raymond James analyst Justin Jenkins has maintained a Strong Buy rating on Darling Ingredients (NYSE:DAR) but lowered the price target from $80 to $75.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:42 pm

JAZZ

Needham analyst Ami Fadia maintains a 'Buy' rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) but lowers the price target from $226 to $225.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:41 pm

FTCI

Raymond James analyst Pavel Molchanov maintains a Strong Buy rating on FTC Solar (NASDAQ:FTCI) but has lowered the price target from $4 to $2.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:40 pm

LYEL

HC Wainwright & Co. analyst Mitchell Kapoor maintains a 'Buy' rating on Lyell Immunopharma (NASDAQ:LYEL) but lowers the price target from $9 to $8.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:38 pm

LITE

Raymond James analyst Simon Leopold has maintained an 'Outperform' rating on Lumentum Holdings (NASDAQ:LITE) and raised the price target from $49.5 to $54.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:38 pm

MIXT

Raymond James analyst Alexander Sklar has maintained an 'Outperform' rating on MiX Telematics (NYSE:MIXT) but lowered the price target from $10 to $8.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:37 pm

CSGS

Wells Fargo has initiated coverage on CSG Systems Intl (NASDAQ:CSGS) with an Equal-Weight rating and a price target of $49.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:34 pm

RANI

HC Wainwright & Co. analyst Mitchell Kapoor maintains a 'Buy' rating on Rani Therapeutics Hldgs (NASDAQ:RANI) but lowers the price target from $20 to $16.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:34 pm

SKYT

Needham analyst Rajvindra Gill maintains a 'Buy' rating on SkyWater Technology (NASDAQ:SKYT) but has lowered the price target from $20 to $13.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:32 pm

CYTK

Goldman Sachs analyst Paul Choi has initiated coverage on Cytokinetics (NASDAQ:CYTK) with a Buy rating and a price target of $50.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:31 pm